Thalia Therapeutics (LON:THAT – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported GBX (0.09) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Thalia Therapeutics Trading Up 4.0%
THAT opened at GBX 0.65 on Friday. Thalia Therapeutics has a twelve month low of GBX 0.40 and a twelve month high of GBX 0.95. The stock has a market cap of £11.54 million and a P/E ratio of -3.82.
About Thalia Therapeutics
RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.
Recommended Stories
- Five stocks we like better than Thalia Therapeutics
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
Receive News & Ratings for Thalia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thalia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
